Alternative Health Blog

In a study involving a mouse model of Alzheimer's disease, treatment with coenzyme Q10 was found to decrease area and number of plaque in the hippocampus and in the overlying cortex immunostained with an Abeta42-specific antibody. Furthermore, brain Abeta42 levels were also decreased, as were levels of amyloid-beta protein precursor beta-carboxyterminal fragements, as a result of supplementation with CoQ10 as well. During a water maze tests, the mice treated with coenzyme Q10 showed cognitive improvement. The authors conclude, "Our results show decreased pathology and improved behavior in transgenic AD mice treated with the naturally occurring antioxidant compound CoQ10. CoQ10 is well tolerated in humans and may be promising for therapeutic trials in AD."